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Abnormalities of skeletal muscle have been described in 
patients with dilated and hypertrophic cardiomyopathy. 
Eleven patients with dilated and eight with hypertrophic 
cardiomyopathy without overt symptomatic skeletal myop- 
athy underwent extensive neuromuscular studies. Quanti- 
tative electromyography showed abnormal reduction of 
motor unit potential duration, indicative of myogenic my 
opathy, in four patients (36%) with dilated and in three 
(37%) with hypertrophic cardiomyopathy. Values were 
21% to 40% (mean 28%) lower than those in age-matched 
normal control subjects. The presence of normal nerve 
conduction velocities and of normal motor unit fiber density 
in all patients indicated lack of neurogenic abnormalities. 
Skeletal muscle biopsy was performed in five patients 
with dilated and in four with hypertrophic cardiomyopa- 
thy. In all nine patients light and electron microscopy 
showed central hyporeactive cores, selective atrophy and 
mitochondrial abnormalities of type 1 fibers but not of type 
2 fibers. The degree of impairment of left ventricular 
function in patients with electromyographic abnormalities 
was similar to that of those without (percent fractional 
shortening at two-dimensional echocardiography 21 f 9 
versus 25 f 10, ejection fraction at angiography 39 f 13% 
versus 42 + 13% and left ventricular end-diastolic pressure 
21 + 6 versus 21 + 8 mm Hg) as well as symptom duration 
(9 + 4 versus 12 f 8 months). 
Thus, subclinical electromyographic alterations indica- 
tive of myogenic myopathy are frequent in patients with 
dilated and hypertrophic cardiomyopathy and are unre- 
lated to the degree of impairment of left ventricular func- 
tion. The concomitant histologic alterations, characterized 
by selective type 1 atrophy, are similar to those observed in 
congenital and idiopathic myopathies, but different from 
those described in secondary heart failure. 
(J Am Co11 Cardiol1989;14:1464-73) 
After the first histopathologic study by Shafiq et al. (l), 
several authors (2-9) showed the existence of a broad 
spectrum of electromyographic or histologic abnormalities, 
or both, in skeletal muscle of patients with dilated (2-4) and 
hypertrophic cardiomyopathy (5-9). However, no consensus 
exists as to whether these abnormalities are neurogenic (8,9) 
or myogenic (2-7) in origin. To establish the nature of 
skeletal muscle abnormalities in patients with primary myo- 
cardial disease, 11 patients with dilated and 8 patients with 
hypertrophic cardiomyopathy were submitted to extensive 
neuromuscular studies. Assessment of skeletal muscle func- 
tion was based on standard and computerized quantitative 
electromyographic studies, light and electron microscopic 
analysis and determination of mitochondrial oxidative en- 
zyme levels in skeletal muscle biopsy specimens. 
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Methods 
Study patients (Table 1). Thirty patients with primary 
myocardial disease were admitted to our department from 
January 1985 to September 1986. Nineteen of them form the 
basis of this report; the others would not consent to enter 
this study. Eleven of the 19 patients (8 men, 3 women, mean 
age 48.6 + 13.8 years) had dilated cardiomyopathy; 8 pa- 
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Table 1. Clinical, Echocardiographic and Hemodynamic Characteristics of the 19 Study Patients 
Clinical Echocardiographic 
Symptom Effort Max 
Patient Genderi Duration NYHA Chest LVIDd WT 
No. Age (yr) (mo) Class Palpitation Pain Syncope (cm) %FS (cm) 
Hemodynamic 
LV 
PCWP LVEDP EF Gradient 
(mm Hg) (mm Hg) (%) (mm I&) 
DCM 
1 
2 
3 
4 
5 
6 
8 
9 
10 
11 
HCM 
12 
13 
14 
15 
16 
17 
18 
19 
M/55 12 I 
Ml19 10 I 
F/30 24 II 
M/48 7 II 
M/60 12 II 
M/55 7 III 
F/64 6 III 
Ml56 5 III 
Ml53 5 III 
Ml39 7 III 
FlS6 6 III 
Ml47 _ I 
Ml47 12 I 
Ml47 24 I 
M/40 10 I 
F/27 7 II 
Ml38 24 II 
M/41 12 II 
F/48 15 III 
t 
t 
t 
_ 5.9 27 0.7 II 13 45 _ 
_ 5.8 23 0.7 12 14 40 _ 
_ 6.0 25 0.9 13 14 36 _ 
_ 6.5 25 0.8 12 13 40 _ 
_ 6.0 27 1.1 15 25 43 - 
_ 6.5 10 1.2 27 22 25 _ 
_ 6.7 13 1.1 25 20 27 - 
_ 6.5 15 1.3 25 19 28 _ 
_ 6.6 15 0.9 20 21 30 _ 
_ 7.4 5 0.8 34 39 20 _ 
_ 6.7 10 0.7 28 33 25 _ 
_ 5.0 36 1.7 
t _ 5.2 34 1.8 
t t 4.8 35 2.2 
t _ 5.0 37 2.4 
t t 4.5 32 2.3 
f t 4.7 30 1.9 
_ _ 5.0 27 2.4 
_ _ 5.5 25 2.2 
5 
10 
I1 
13 
14 
14 
14 60 _ 
15 60 40 
13 52 45 
17 62 35 
30 40 65 
30 50 55 
22 47 84 
20 45 45 
DCM = dilated cardiomyopathy; EF = ejection fraction; %FS = % fractional shortening; HCM = hypertrophic cardiomyopathy; LV = left ventricular; 
LVEDP = left ventricular end-diastolic pressure; LVIDd = left ventricular internal end-diastolic dimension; Max WT = maximal (septal) wall thickness; NYHA 
= New York Heart Association classification; PCWP = mean pulmonary capillary wedge pressure; - = absent; t = present. 
tients (6 men, 2 women, mean age 44.2 + 13.8 years) had 
hypertrophic cardiomyopathy (7 obstructive, 1 nonobstruc- 
tive; all of them had asymmetric septal hypertrophy). Mean 
body weight was 71 2 10 kg; all patients were within the 
range of the ideal weight (10). 
At the time of examination, six were in New York Heart 
Association functional class I, six in class II and seven in 
class III. Cardiovascular assessment was performed 1 to 3 
weeks before entering the study and included M-mode and 
two-dimensional echocardiography, right and left sided car- 
diac catheterization, selective coronary arteriography and 
left ventriculography in two orthogonal projections. 
Diluted cardiomyopathy was diagnosed according to the 
World Health Organization criteria (11,12). Hypertrophic 
cardiomyopathy was diagnosed according to accepted clas- 
sifications, in the presence of unexplained left ventricular 
hypertrophy (13,14). No patient had a history of myocardi- 
tis, coronary artery disease, systemic hypertension, periph- 
eral vascular disease, diabetes mellitus or excessive ethanol 
consumption, or a history or signs of renal failure, hereditary 
or acquired neuromuscular disorders or associated syn- 
dromes; nor had any patient consumed neurotoxic drugs, 
including those that cause axonal neuropathy (15). Clinical 
findings are summarized in Table 1. All patients gave writ- 
ten, informed consent as approved by the local Ethics 
Committee. 
Neuromuscular assessment. A detailed clinical history 
and physical examination were performed. The Medical 
Research Council grading system (16,17) was applied to 
quantitate segmental strength in the following muscles: 
deltoid, biceps and triceps brachii, extensor carpi, quadri- 
ceps femoris and foot dorsal flexors. Serum determinations 
were performed for creatine kinase, myoglobin, lactate in 
basal conditions and after a 10 min forearm ischemic test 
(18), and carnitine, both in its free and esterified forms (19). 
Electromyographic studies. In all patients qualitative 
evaluation of skeletal muscle function was obtained by a 
standard electromyographic test and interference pattern 
analysis at maximal voluntary contraction in the right biceps 
brachii muscle (20). Spontaneous activity (fibrillation, posi- 
tive sharp waves) at the standard test or recruitment with 
fast firing rate at interference pattern analysis, or both, were 
considered qualitative indexes of neurogenic damage (21). 
Objective assessment of skeletal muscle abnormalities of 
myogenic origin at quantitative electromyographic analysis 
was based on the following determinations: 1) single motor 
unit potential duration (13 patients) in vastus medialis (OTE- 
Basis SO9 program, single motor unit), calculated as the 
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mean of 20 values obtained from different sites of the muscle 
(20); 2) ratio between mean amplitude of turns and mean turn 
count per s, of an interference pattern in the right biceps 
brachi muscle (18 patients), according to Willison analysis 
(22-24); and 3) muscle fiber conduction velocity in the left 
biceps brachii short head (18 patients), calculated as the 
mean of values from 20 different fibers (25). 
Table 2. Results of Quantitative Electromyographic Analysis 
in the 19 Study Patients 
Patient 
No. 
Single Motor Unit 
Potential Duration 
(ms)* 
Muscle 
Fiber 
Conduction Willison 
Velocity Ratio Fiber 
(m/s) (mV/tums) Density 
Objective assessment of skeletal muscle abnormalities of 
neurogenic origin was based on the following determina- 
tions: 1) sensory and motor nerve conduction velocities in 
the upper limb (left ulnar nerve) and lower limb (left sural 
nerve) in 19 patients (20) and 2) motor unit fiber density in 
the extensor digitorum communis muscle (13 patients), cal- 
culated as mean number of potentials from 20 different 
positions of the recording electrode (26). Values were con- 
sidered abnormal when they exceeded 2 SD from the mean 
control value for our laboratory. Only single motor unit 
potential duration was compared with Buchthal age-matched 
control values (27). To assess reproducibility between our 
measurements and those from Buchthal’s laboratory we had 
previously determined single motor unit potential duration in 
10 normal subjects aged 25-35 years, and the values obtained 
(mean + SD 11.3 + 1.1 ms) were similar to age-matched 
reference values (27). 
DCM 
1 11.80 (13 + 1.30) (N) 
2 0 
3 9.47 (11.1 + 1.10) (N) 
4 10.00 (13.0 + 1.30) (J, 
5 12.54 (13.7 + 1.35) (N) 
6 10.62 (13.4 + 1.30) (4, 
7 0 
8 0 
9 8.26 (13.4 + 1.30) (1) 
10 0 
II 9.77 (13.4 + 1.30) (1) 
HCM 
12 10.15 (12.5 + 1.25) (N) 
13 8.14 (12.5 + 1.25) (J, 
14 10.70 (12.5 t 1.25) (N) 
I5 9.85 (12.2 2 1.25) (N) 
16 0 
17 0 
18 9.86 (12.5 * 1.25) (I, 
19 9.68 (13.0 k 1.30) (1) 
Normal * 
3.74 (N) 
3.98 (N) 
3.84 (N) 
0 
4.82 (N) 
4.44 (N) 
3.29 (N) 
3.88 (N) 
3.59 (N) 
2.72 ( 1) 
5.09 ( t ) 
1.99 (N) 
I .98 (N) 
1.72 (N) 
1.43 (N) 
1.61 (N) 
1.85 (N) 
1.29 (N) 
1.47 (N) 
1.56 (N) 
1.63 (N) 
1.58 (N) 
I .65 (N) 
1.17 (N) 
1.65 (N) 
I .30 (N) 
0 
1.40 (N) 
1.35 (N) 
0 
0 
0 
1.45 (N) 
Muscle biopsy. Nine patients underwent open muscle 
biopsy. In six it was performed in the right biceps brachii and 
in three in the right deltoid muscle. The specimens were 
separated into three parts; two of them were cooled for 10 to 
15 s in an isopentane bath immersed in -160°C liquid 
nitrogen and kept at -80°C for light microscopic and bio- 
chemical examination. The third fragment was immersed in 
2.5% phosphate-buffered glutaraldehyde for electron micros- 
copy. Light microscopy was performed after staining with 
hematoxylin-eosin, modified Gomori trichrome, periodic ac- 
id-Schiff, oil-red-O, reduced diphosphopyridine nucleotide- 
tetrazolium reductase and alkaline adenosine triphosphatase 
(pH 9.4). Electron microscopy was performed as previously 
described (28,29). Percent distribution of type 1 and 2 fibers, 
mean diameter, diameter variability coefficient, atrophy and 
hypertrophy factors in both type 1 and 2 fibers were calcu- 
lated (28). Mean diameter was considered to be reduced in 
patients in whom it was lower than the lowest value of the 
normal range according to Dubowitz and Brooke (28). 
3.31 (N) 
3.75 (N) 
3.95 (N) 
3.02 (4 1 
3.45 (N) 
3.58 (N) 
4.19 (N) 
3.48 (N) 
1.47 (N) 
1.59 (N) 
0 
1.75 (N) 
1.29 (N) 
I .42 (N) 
I .64 (N) 
I .30 (N) 
I .35 (N) 
1.23 (N) 
I .30 (N) 
0 
I .30 (N) 
0 
1.46 (N) 
1.45 (N) 
4.07 + 0.40 
(n = 23) 
1.33 ? 0.46 
(n = 15) 
Age <SO: 
1.49 + 0.16 
Age >50: 
1.57 * 0.17 
*Age- and gender-matched values for single motor unit potential duration 
(mean k SD) according to Buchthal (27) are indicated in parentheses. N = 
normal value; d = reduced value (<mean - 2 SD); t = enhanced value 
(>mean t 2 SD); 0 = not done; other abbreviations as in Table 1. 
Free and esterified carnitine radioimmunoassay and spec- 
trophotometric assay (19) of citrate synthetase, succinic 
dehydrogenase, reduced diphosphopyridine nucleotide de- 
hydrogenase, succinic-cytochrome C-reductase, reduced 
diphosphopyridine nucleotide-cytochrome C-reductase and 
cytochrome C-oxidase were carried out in two patients with 
dilated and in four with hypertrophic cardiomyopathy. En- 
zyme activities were considered abnormally reduced when 
lower than the lowest value of the normal range as reported 
by Angelini et al. (19). 
Statistical analysis. Ventricular function and symptom 
duration in patients with and without electromyographic 
abnormalities were compared by Student t test for unpaired 
data. The mean values of atrophy factors in patients in the 
different functional classes were compared with use of 
one-way analysis of variance. Fisher’s exact test was used to 
compare proportions of patients with electromyographic 
abnormalities belonging to pairs of the different functional 
classes. Statistical significance was defined as p < 0.05. All 
data are expressed as mean values ? 1 SD. 
Results 
Neuromuscular clinical findings. Medical history revealed 
the occurrence of muscular pain in three patients (27%) with 
dilated cardiomyopathy and in five (62%) with hypertrophic 
cardiomyopathy. It was mostly described as sporadic, oc- 
curring at rest and located in forearms or calves. All symp- 
tomatic patients with dilated and one patient with hyper- 
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Table 3. Morphometric Findings of Muscle Biopsy in 9 Patients 
Patient 7c 
No. Distribution 
_____ 
DCM 
I 37 (N) 
6 60(f) 
8 38 (N) 
9 41 (N) 
II 33 (N) 
HCM 
12 41 (N) 
14 38 (N) 
16 42 (N) 
18 41 (N) 
Normal 
Male 
555% 
Female 
Type 1 Fibers Type 2 Fibers 
Mean Diameter Mean Diameter 
Diameter Variability Atrophy % Diameter Variabiity Atrophy 
(p) Coefficient Factors Distribution (IL) Coefficient Factors 
39.8 ( 4 ) 220 (N) 400(t) 63 (N) 50.2 (N) 164 (N) 90 (N) 
41.0 (N) 238 (N) 680 ( t 1 40 (N) 50.7 (N) 189 (N) 120 (N) 
41.1 (N) 243 (N) 620 ( f ) 62 09 53.8 (N) 184 (N) 80 (N) 
37.7 ( 1) 249 (N) 800(f) 59 (N) 49.6 (N) 147 (N) 40 (N) 
36.3 (N) 170 (N) 160(f) 62 (N) 39.4 (N) 178 (N) 80 (N) 
38.4 ( 1) 242 (N) 760 ( T ) 59 (N) 66.7 (N) 199 (N) 40 (N) 
41.7 (N) 134 (N) 400(f) 62 (N) 52.9 (N) 128 (N) 25 (N) 
47.7 (N) 226 (N) 80 (N) 58 (N) 40.2 (N) 176 (N) 80 (N) 
45.6 (N) 222 (N) 400 ( t 1 59 (N) 56.3 (N) 181 (N) 40 (N) 
40 to 80 5150 40 to 80 
5250 ~80% 2250 5150 
30 to 70 5100 30 to 70 
*See reference 28. Abbreviations and symbols as in Tables 1 and 2 
trophic cardiomyopathy also showed a slight hyposthenia in 
girdles or proximal limbs, or both (score 4 on Medical 
Research Council scale), but not in the distal muscles of 
upper and lower limbs. All of them were in New York Heart 
Association functional class III. No patient had muscular 
hypotrophy. Serum creatine kinase, myoglobin, free car- 
nitine and lactate values after the ischemic test were normal 
in all patients. Esterified carnitine was reduced in one patient 
with hypertrophic cardiomyopathy. 
Electromyographic studies (Table 2). At standard electro- 
myography, myogenic motor unit potential morphology (re- 
duced amplitude and duration, enhanced polyphasia) was 
observed in one patient with dilated and in three patients 
with hypertrophic cardiomyopathy. Quantitative electromy- 
ography yielded abnormal results in these four patients and 
in five other patients (four with dilated and one with hyper- 
trophic cardiomyopathy). The following abnormalities, typ- 
ical of myogenic myopathy (20,25,27), were found: 1) reduc- 
tion of single motor unit potential duration in three patients 
with dilated and three with hypertrophic cardiomyopathy; 2) 
alteration of muscle fiber conduction velocity in two patients 
(one with dilated and one with hypertrophic cardiomyopa- 
thy); and 3) both reduction of single motor unit potential 
duration and alteration of muscle fiber conduction velocity in 
one patient with dilated cardiomyopathy. Willison ratio was 
within the normal range in all patients. No patient showed 
signs of neurogenic alteration (spontaneous activity, recruit- 
ment with fast firing rate, reduction of nerve motor and 
sensory conduction velocities) (20.26). 
Muscle Biopsy Findings (Table 3) 
Light microscopy. Pathologic changes of type 1 fibers 
were detected in all nine patients from whom a biopsy 
specimen was obtained (Fig. 1). Type 1 fiber abnormalities 
included central hyporeactive cores (Fig. 2) or strong sub- 
NYHA I III 
Figure 1. Relation between myogenic abnormalities and f 
~~~~ i 
New York Heart Association (NYHA) functional class. m 0 
DCM = dilated cardiomyopathy; EMG = electromyog- ?W9 ?V9 ? 
raphy; HCM = hypertrophic cardiomyopathy. i\ I IAA I IIA I 
B’OPSY .@ @ @.@.@ ‘@ . . .@ @ 
I =abnormal 0 =normal @ =not done / 
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Figure 2. Case 11 (dilated cardiomy- 
opathy. Skeletal biopsy: light micros- 
copy. Arrows indicate atrophic type 1 
fibers with evident central hyporeac- 
tive cores. (Reduced diphosphopyri- 
dine nucleotide-tetrazolium reduc- 
tase stain, original magnification 
x200, reduced by 30%.) 
sarcolemmal reaction to reduced diphosphopyridine nucleo- 
tide-tetrazolium reductase (Fig. 3), or both. Morphometric 
analysis of type 1 fibers showed increases of atrophy factors 
in eight of the nine biopsies (mean increase compared with 
sex-matched normal values were 371%), reduced fiber mean 
diameter in three patients (two with dilated and one with 
hypertrophic cardiomyopathy) and type 1 fiber prevalence 
in one patient with dilated cardiomyopathy (Table 3). No 
alteration of type 2 fibers was observed in any patient (Table 
3). 
Of these nine patients, four, whose biopsy specimen was 
obtained from the biceps brachii muscle, had abnormal 
results in this muscle at qualitative electromyography and 
abnormal results in the vastus medialis at quantitative elec- 
tromyography. The five patients in whom the biopsy was 
performed in the deltoid (three patients) or in the biceps 
brachii (two patients), had normal electromyographic results 
(Fig. 1). 
Electron microscopy. Minimal abnormalities of the myo- 
filaments, such as small focal areas with myofibril loss and 
disruption of the normal banding patterns, were present in 
two patients with dilated and in three with hypertrophic 
cardiomyopathy. Lipid vacuoles, scattered along the myo- 
fibrils, were detected in three patients with dilated and in 
Figure 3. Case 9 (dilated cardiomyop- 
athy). Skeletal biopsy: light micros- 
copy showing strong reaction of sub- 
sarcolemmal region in type 1 fibers 
(arrows). (Reduced diphosphopyri- 
dine nucleotide-tetrazolium reduc- 
tase stain, original magnification 
x300, reduced by 30%.) 
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Figure 4. Case 18 (hypertrophic cardiomyopathy). Skel- 
etal biopsy: electron microscopic ultra thin section 
showing many lipid droplets (arrows) among myofibrils 
(Original magnification x 15,000, reduced by 20%.) 
three with hypertrophic cardiomyopathy; in two patients 
with hypertrophic cardiomyopathy they were particularly 
large and numerous (Fig. 4). Mitochondrial abnormalities, 
manifest as swelling with clarification of the matrix, cristol- 
ysis and collections of normal or degenerated mitochondria 
beneath the sarcolemma or in widened spaces between 
normal or damaged myofibrils, were detected in all patients 
in both groups (Fig. 5 and 6). 
Biochemistry (Table 4). Muscle and serum esterified car- 
nitine levels were abnormally reduced in one patient with 
hypertrophic cardiomyopathy. Mitochondrial enzymatic ac- 
tivities were reduced for one or more enzymes in one of two 
patients with dilated and in three of four with hypertrophic 
cardiomyopathy. Specifically, succinic cytochrome C- 
reductase was reduced in four patients, reduced diphos- 
phopyridine nucleotide-dehydrogenase and reduced diphos- 
phopyridine nucleotide-cytochrome C-reductase were 
reduced in 2 and succinic dehydrogenase was reduced in 1 
patient. Cytrate synthetase and cytochrome-C-oxidase were 
normal. 
Relation Between Myopathy and 
Cardiac Function 
Echocardiographic and hemodynamic indexes of ventric- 
ular function in patients with electromyographic abnormali- 
ties were similar to those of patients without (echocardio- 
graphic percent fractional shortening 21 t 9 versus 25 f 10; 
angiographic percent ejection fraction 39 t 13 versus 42 t 
13; left ventricular end-diastolic pressure 2 I k 6 versus 21 ? 
8 mm Hg, all p = NS) as was symptom duration (9 2 4 
versus 12 + 8 months, p = NS). 
Electromyogruphic abnormalities are slightly but not 
significantly more common in patients in functional class III 
(5 of 7. 71%) than in those in class I (2 of 6, 33%) or II (2 of 
6, 33%) (Fig. I). 
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Figure 5. Case 12 (hypertrophic nonobstructive cardio- 
myopathy). Skeletal biopsy. Electron microscopy 
shows evidence of severe mitochondrial degenerative 
changes (swelling, loss of cristae, clarification of the 
matrix); arrows indicate lipid droplets among mitochon- 
dria. (Original magnification x 15,000, reduced by 20%.) 
Type 1 fiber atrophy factors, indexes of the severity of 
myopathic changes, were similar in patients in functional 
class I, II and III (mean increases 371%, 173%, 390%, 
respectively, p = NS). 
Discussion 
Electromyographic evidence of myogenic myopathy. Our 
study provides an objective assessment of skeletal muscle 
function by quantitative electromyography in patients with 
dilated and hypertrophic cardiomyopathy. Skeletal muscle 
abnormalities, in particular reduction of single motor unit 
potential duration, were found in about 40% of patients with 
dilated or hypertrophic cardiomyopathy who had no evi- 
dence of overt clinical skeletal myopathy. In the absence of 
traumatic nerve lesions or disorders of neuromuscular trans- 
mission, or both, neither of which was present in our 
patients, these findings are specific for myogenic myopathy 
(20). In no patient were objective signs of neurogenic alter- 
ation, such as reduction of nerve conduction velocities, 
increase in single motor unit potential duration, Willison 
ratio or motor unit fiber density, observed (2&24,26). Al- 
though this latter variable was determined in the upper limbs 
only, because chronic edema or lumboarthrosis at a subclin- 
ical stage may interfere with its determination in the leg 
muscles (15,26), peripheral neuropathies may be ruled out 
because they usually affect distal muscles of both upper and 
lower limbs and result in reduced nerve conduction veloci- 
ties (15,20). 
Axonaf neuropathies, which may primarily affect distal 
leg muscles with normal nerve conduction velocities (15), 
were ruled out in our patients. These rare diseases, often 
severely symptomatic, are either hereditary or toxic (15) and 
were excluded on clinical grounds. 
Our results also show that standard electromyography is 
less sensitive than quantitative electromyography in detect- 
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Figure 6. Case 18 (hypertrophic cardiomyopathy). Skel- 
eta1 biop ~sy. Electron microscopy of a muscle fiber 
showing extensive subsarcolemmal accumulation of 
pyknotic mitochondria (arrows). (Original magnification 
x20,000, reduced by 20%.) 
Table 4. Mitochondrial Enzymatic Activities in Muscle Biopsy (~moliminig wet weight) in Six Patients 
Patient 
No. 
Citrate 
Synthetase 
Cytochrome-C 
Oxidase 
Reduced 
Diphosphopyridine 
Nucleotide 
Cytochrome-C 
Reductase 
Reduced 
Diphosphopyridine 
Nucleotide 
Dehydrogenase 
Succinic 
Cytochrome-C 
Reductase 
Succinic 
Dehydrogenase 
DCM 
9 14.33 (N) 2.59 (N) 2.70 (N) 33.87 (N) 0.70 (N) 0.62 (N) 
II 16.17 (N) 1.21 (N) I .94 (N) 25.16 ( 4 ) 0.50 ( 1 ) 0.58 (N) 
HCM 
12 17.20 (N) 1.84 (N) I .45 ( J ) 45.16 (N) 0.54 ( i ) 0.62 (N) 
14 12.31 (N) 2.27 (N) 2.70 (N) 35.48 (N) 0.75 tN) 0.58 (N) 
16 13.23 (N) 2.10 (N) 2.37 (N) 38.70 (N) 0.51 c 4 ) 0.62 (N) 
18 17.64 (N) 1.37 (N) 1.06 (J 1 26.77 (4) 0.44 ( 1 ) 0.50 ( 5 ) 
Normal 10.14 to 18.38 1.10 to 4.41 1.89 to 7.02 33.64 to 66. I2 0.70 to I.81 0.5 I to 2.02 
(n = 12) 
Abbreviations and symbols as in Tables I and 2. 
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ing myopathies. This could explain why other investigators 
did not find skeletal muscle abnormalities in patients with 
dilated or hypertrophic cardiomyopathy (8,9). 
Histologic evidence of myogenic myopathy, In this study 
skeletal muscle biopsy always confirmed the presence of 
myogenic myopathy as indicated by selective type 1 fiber 
alterations. Electromyographic and histopathologic abnor- 
malities were similar in patients with dilated and those with 
hypertrophic cardiomyopathy. These findings are intriguing 
and no clear explanation is available. The selective type 1 
fiber atrophy described in this study, similar to that de- 
scribed in congenital and idiopathic myopathies (1,29-39) 
has not been previously reported in patients with dilated and 
hypertrophic cardiomyopathy. Others (3,4) reported type 2 
fiber atrophy in patients with dilated cardiomyopathy. How- 
ever, type 2 fiber atrophy is not specific for myogenic 
myopathy; it is also seen in neurogenic atrophy (30), disuse 
atrophy (29) and, in particular, in peripheral vascular disease 
(40,41) and cardiac failure (1,42). The selective involvement 
of type 1 fibers, which have predominant oxidative metabo- 
lism, and the reduced activity of mitochondrial oxidative 
enzymes are in agreement with findings of recent studies 
using nuclear magnetic resonance spectral analysis, which 
show impaired oxidative metabolism in skeletal muscle of 
patients with cardiomyopathy whether or not heart failure is 
present (43,44). 
Histologic myogenic changes were detected even in the 
absence of functional abnormalities in five patients, suggest- 
ing that such changes are an earlier marker of myogenic 
myopathy. Sequential biopsies and electromyographic stud- 
ies might better delineate the natural history of the myo- 
pathic involvement in patients with cardiomyopathy. How- 
ever, the invasive nature of the procedure represents an 
objective limitation of this approach. 
The mechanism of myogenic myopathy in our patients is 
unknown. In one patient, who had severe ultrastructural 
mitochondrial changes and reduced concentrations of car- 
nitine fractions both in serum and in muscle, a defect in 
carnitine esteritication was postulated as a mechanism (32- 
35). 
Relation between skeletal myopathy and heart failure. The 
design of the present study does not allow us to establish 
whether myopathic changes are primary or secondary to 
heart failure. However, the following observations argue 
against the latter possibility: 1) selective type 1 atrophy is 
typically observed in congenital or idiopathic myopathies 
(29-32) but not in secondary heart failure (1,42); 2) the 
severity of myogenic myopathy, as assessed by type 1 fiber 
atrophy factors, was similar among patients in cardiac func- 
tional classes I, II and III; 3) echocardiographic and hemo- 
dynamic indexes of left ventricular function were similar in 
patients with and without electromyographic abnormalities; 
and 4) the proportions of patients with electromyographic 
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abnormalities were not statistically different in the three 
functional classes. 
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